Friday, February 21, 2020 12:23:55 PM
Recent INDP News
- Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data • GlobeNewswire Inc. • 10/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/10/2024 08:05:15 PM
- Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy • GlobeNewswire Inc. • 10/10/2024 12:00:00 PM
- Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/08/2024 12:00:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 10/04/2024 09:21:50 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/12/2024 08:45:11 PM
- Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses • GlobeNewswire Inc. • 09/05/2024 12:30:00 PM
- Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/12/2024 12:16:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 12:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:00:28 PM
- Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:00:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/07/2024 09:28:25 PM
- Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 09:23:56 PM
- Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:30:38 PM
- Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM